This story was first published in digitalhealth.net

People with advanced kidney cancer are set to benefit from a new treatment after NICE has said lenvatinib should be available on the NHS.
The drug is recommended as an option for people who have previously been treated for advanced real cell carcinoma (RCC).
Lenvatinib works by blocking the signals that a cancer cell needs to grow and divide.
The evidence from a clinical trial suggests that, on average, people live around 10.1 months longer if they have lenvatinib plus everolimus rather than everolimus alone.
A revised offer from the company also means the NICE committee found the treatment cost effective.
This means they will now recommend lenvatinib (plus everolimus) as an option for advanced RCC in adults who have had one previous treatment with vascular endothelial growth factor (VEGF)-targeted therapy.
This story was first published in digitalhealth.net
UK Building Regulations highlight toxic gas and smoke from layers of paint built up over multiple redecorations as a major cause of permanent ill health or death in a building fire.
Their concern rose with discovery the flame retardant paints most widely used paint along escape routes have been ones which to this day counter-productively use emission of heavy toxic gas to smother flames which rapidly spread along walls if layers of paint delaminate in a fire.
Northwich’s Victoria Infirmary (VIN) Community Diagnostic Centre (CDC) has enabled more patients
Adveco, the commercial hot water specialist, announces the launch of live metering of domestic ho
Sarah Greenslade, public affairs and communications officer at the British Parking Association looks at some of the problems and innovations in healthcare parking
It’s easy to assume that the comms team is there to handle press enquiries and the occasional social media storm – but the reality is that strategic communications can make a measurable impact across the entire organisation, from operational to financial, when done properly